JAK2 and head and neck squamous cell carcinoma: Furthermore, both in vivo and in vitro JAK2 inhibitors have demonstrated to reduce HNSCC proliferation in previous study [129]; Ruxolitinib, a JAK1/2 inhibitor approved for myelofibrosis, has being evaluated in operable HNSCC (NCT03153982).